Lyra Therapeutics, Inc.
LYRA
$7.47
$0.131.77%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -7.44M | -8.55M | -10.98M | -11.87M | -48.13M |
| Total Depreciation and Amortization | 127.00K | 128.00K | 151.00K | 39.00K | 145.00K |
| Total Amortization of Deferred Charges | -- | -- | 0.00 | 0.00 | 140.00K |
| Total Other Non-Cash Items | 906.00K | 825.00K | 1.67M | 1.09M | 25.17M |
| Change in Net Operating Assets | -186.00K | -1.25M | -2.20M | -5.48M | 2.70M |
| Cash from Operations | -6.59M | -8.84M | -11.35M | -16.22M | -19.98M |
| Capital Expenditure | -20.00K | -- | 58.00K | -51.00K | -196.00K |
| Sale of Property, Plant, and Equipment | 18.00K | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | 28.07M | 8.19M | 36.37M |
| Cash from Investing | -2.00K | -- | 28.13M | 8.14M | 36.18M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 5.00M | -- | -- | 0.00 | 9.00K |
| Repurchase of Common Stock | -- | -- | -1.00K | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -358.00K | -- | 0.00 | -23.00K | -98.00K |
| Cash from Financing | 4.64M | -- | -1.00K | -23.00K | -89.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -1.95M | -8.84M | 16.78M | -8.11M | 16.11M |